A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS-7535 in Subjects With Heart Failure With Preserved Ejection Fraction and Obesity
Latest Information Update: 02 May 2025
At a glance
- Drugs HRS-7535 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Shandong Suncadia Medicine
Most Recent Events
- 23 Apr 2025 Status changed from not yet recruiting to recruiting.
- 18 Feb 2025 New trial record